IsoPlexis research offers hope for targeted CAR-T treatment – The Pharma Letter (registration)
|
IsoPlexis research offers hope for targeted CAR–T treatment
The Pharma Letter (registration) US-based biotech firm IsoPlexis has presented findings from research using the company's precision engineering platform, called IsoCode. The data show the potential to predict whether cancer patients will respond to CAR–T cell therapy prior to … |
